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energy expenditure. ‘Exercise’ refers to planned, structured and repetitive
movement to improve or maintain one or more components of physical
fitness (Chodzko-Zajko et al, 2009). So a person may take little exercise but be
physically active with low levels of sedentary behaviour, whereas another
might do structured exercises but be habitually inactive and spend long
periods sedentary. Thus, the end points of some of the reviewed trials and the
methods used to measure those end points require more critical discussion.
For example, the authors acknowledge that aerobic exercise tolerance may not
reflect aerobic fitness – but neither of those necessarily translates into
improved habitual physical activity. The authors acknowledge the challenge of
achieving current physical activity guidelines, but do not mention potential
end points at the lower end of the physical activity continuum – for example,
breaking up sedentary behaviour with light activity – which may be critical in
cancer survivors, given recent recognition of the adverse health consequences
of high levels of sedentary behaviour in cancer populations (Lynch et al, 2013).
We would also like to draw particular attention to differences between the
reviewed studies in the methods used to measure physical activity end points,
such as self-report measures, heart rate monitors and accelerometers. Two
studies (Pinto et al, 2005, 2013) included in the analysis showed that self-
report measures did not correspond with objectively measured physical
activity, which we also found in both an observational (Broderick et al, 2013b)
and an intervention study (Broderick et al, 2013a). Unless sedentary behaviour
and all physical activity, including exercise, are accurately, consistently and
objectively measured across studies, using, for example, accelerometers, we
think it will be impossible to answer the ‘million dollar’ question of how best
to improve habitual physical activity and adherence to guidelines for health
benefits in cancer patients and survivors.
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Sir,
We thank Broderick et al (2014) for their interest in our manuscript. We
agree there seems to be uncertainty in the terminology around exercise
interventions, which has not been helped by the implication of a distinction
between the terms ‘physical activity’ and ‘exercise’ in some publications
(Chodzko-Zajko et al, 2009). A more constructive approach would appear to
be that taken by Winter and Fowler, (2009) in defining and quantifying
exercise according to the Systeme International d’Unites. As stated in the
review, this is the approach we chose to follow, for several reasons:
1. An important aspect of a systematic review is to summarise the current
evidence base with a view to identifying prospective research priorities or
furthering practice. In this context, making a distinction between physical
activity and exercise is unhelpful, particularly in evaluating clinical
effectiveness. As in other clinical trials, most notably drug studies, objective
documentation of the amount of the intervention that is delivered is
imperative to identify dose–response curves and adverse effects. The review
criteria were set to include only studies reporting such objective metrics (i.e.,
frequency, intensity and duration) so as to facilitate reproducibility of the
intervention. Any systematic review of cancer therapies will clearly identify
the target population and objectively define the intervention; exercise is no
different, if we are to take its use as a therapeutic intervention seriously.
2. The term ‘sedentary behaviour’ is open to uncertainty, as considerable
exercise may be taking place in a sedentary (i.e., seated) position—for
example, rowing or cycling. We agree this needs defining, but to do so by
subdividing exercise into different terms, seems counterproductive. Sedentary
behaviour could be defined as anyone not achieving the recommendation to
take 150min per week of moderate-intensity aerobic exercise (Rock et al,
2012). However, in clinical trials involving cancer cohorts, this has frequently
been defined as o90, or even o60min per week (Pinto et al, 2005; Daley
et al 2007; Cadmus et al, 2009; Bourke et al, 2014). The rationale being that
there should be some scope to induce a clinically meaningful benefit from
participation in the intervention. If there is not, why do we need to intervene?
Nevertheless, as we concluded in the review, most individuals living with or
beyond cancer would currently find current guideline targets unachievable,
certainly with current published interventions. More research or a revision of
the one size fits all approach is warranted. We conclude in the review that a
‘dose response’ might be more appropriate. This would include the suggested
‘potential end-points at the lower end of the physical activity continuum.’
Such recommendations might require elucidation by further data collection or
an individual patient data meta-analysis for any given health outcome.
3. The tendency of epidemiological studies to imply a distinction between
exercise and physical activity reflects imprecision of measurement rather
than any fundamental difference. Subjective metrics of exercise behaviour,
for example, metabolic equivalents derived from questionnaires (Ainsworth
et al, 2011), are often used in these reports and we agree that objective
measurement of exercise behaviour are preferable in clinical trials.
Dedicated accelerometers seem an overly expensive option. Less expensive
alternatives such as smartphone applications or simple heart rate monitors
would be welcome where the technology is available, affordable and
contextually appropriate. For individuals on prescribed medication (e.g., b-
blockers) that impact the cardiovascular response to physical exertion, reliable
measurement of dose–response remains a challenge.
Finally, as Jan Swammerdam’s 17th century experiments demonstrated rather
elegantly (Needham, 1971; Winter and Fowler, 2009), skeletal muscles neither
‘contract’ (i.e., reduce in volume) nor expand significantly during exercise.
Furthermore, movement is neither essential nor necessary (as in isometric
activity) for exercise to be taking place. What is fundamental to exercise, in the
context being discussed, is skeletal muscular activity exerting force and
generating a metabolic response i.e. physical activity by a different name.
We look forward to reaching consensus on the role of defined exercise
interventions in the treatment of a number of cancers and agree with Broderick
et al that consensus on terminology is an essential first step. We would
encourage all practitioners in this area to follow the excellent recommendations
of Winter and Fowler, which perpetuate reproducibility rather than confusion.
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Sir,
We read with great interest the article ‘KRAS-mutated plasma DNA as
predictor of outcome from irinotecan monotherapy in metastatic colorectal
cancer’ published by (Spindler et al, 2013) in the December 2013 issue of the
British Journal of Cancer. It is now well established that only patients with
wild-type KRAS metastatic colorectal cancer benefit from treatment with an
anti-epidermal growth factor receptor (EGFR) monoclonal antibody and that
patients with KRAS mutant metastatic colorectal cancer do not (Karapetis
et al, 2008; Douillard et al, 2010). Up until now, DNA from archival tumour
tissue is used to determine KRAS mutations in clinical practice. Increased
recent data indicate that circulating tumour DNA in plasma, could be a new
way to analyse the somatic mutation in tumours and could be a potential
biomarker to ensure optimal treatment (Murtaza et al, 2013). Spindler et al
(2013) aimed to investigate the clinical implication of KRAS and BRAF
mutations in both archival tumour tissue and plasma cell-free DNA in 211
metastatic colorectal cancer patients treated with second-line irinotecan
monotherapy. Authors observed that plasma KRAS mutations, but not
tumour KRAS mutations, were associated with worse disease control rate,
progression-free survival and overall survival. However, contrary to what is
mentioned in the title, the predictive impact of the plasma KRAS and BRAF
mutations for the irinotecan response treatment cannot be evaluated in this
study because there is no control arm (patients receiving other therapies or no
therapy).
In this study, KRAS mutations have been detected less frequently in plasma
(31%) as compared in tumour (45%) (16 patients with a wild-type KRAS
plasma had a mutation in the tumour). Tumour KRAS mutations were
analysed in formalin-fixed paraffin-embedded tissue obtained at diagnosis,
whereas plasma KRAS mutations were analysed in pretreatment blood
samples before the beginning of second-line irinotecan monotherapy. The
description of patients receiving an anti-EGFR in first-line therapy would be
an interesting information, as acquired KRAS mutations can be induced by
these therapies (Misale et al, 2012). The presence of a minority subclone
harbouring KRAS mutations within tumours might explain the secondary
resistance to anti-EGFR therapy (Tougeron et al, 2013) and the emergence of
plasma KRAS mutations (Diaz et al, 2012).
Furthermore, the discordance for the KRAS mutation detection rate between
tumour and plasma could be explained by a lack of sensitivity for the plasma
KRAS mutations detection or by the absence of circulating tumour DNA for
some patients. The amplification refractory mutation system-quantitative PCR
(ARMS-qPCR) methodology, used in this study, has a sensitivity around 0.1%
(Fox et al, 1998; Nordgård et al, 2012). Some studies have suggested that ARMS
has an insufficient sensitivity to detect low levels of KRAS mutation (Nordgård
et al, 2012). Indeed, the level of circulating tumour DNA in plasma can be very
low and may represent only a small fraction of the total circulating DNA
(o0.01%) (Diehl et al, 2008; Taly et al, 2013). Techniques with very high
sensitivity for circulating tumour DNA detection have been recently developed
(Taly et al, 2012), such as microdroplet technology, which can detect one mutant
KRAS gene among 200 000 wild-type KRAS genes in the plasma (Pekin et al,
2011). Thus, we think that the results of the study by Spindler et al (2013) should
be interpreted with caution because the poor prognosis of patients with plasma
KRASmutation could only reflect the poor prognosis of patients with a high level
of circulating tumour DNA, as suggested by some others studies (Lefebure et al,
2010; Spindler et al, 2012). In contrast, the better prognosis could only reflect the
low level of circulating tumour DNA that is not detectable by the ARMS assay
for the KRAS mutation testing.
In conclusion, this promising work published by Spindler et al (2013)
highlights the impact of circulating tumour DNA on the treatment response of
metastatic colorectal cancer. Moreover, it strengthens the need for harmonis-
ing detection methods for KRAS mutations and to develop highly sensitive
techniques for plasma testing. Thus, correlation of KRAS mutation in primary
tumours, metastases and plasma during metastatic colorectal therapies still
needs to be studied.
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